o had no family history of the disease, these patients had more severe prior illness with earlier onset and more hospitalizations, suicide attempts, alcohol abuse and anxiety disorders. The group's average improvement on the CGI was poorer than the other group's, despite being on more medications (3.1 on average) and having been treated for a similar period of time (just under two years).
"When compared to students without a first-degree family history, students with a family history appear to be associated with more severe prior illness, and a poorer longitudinal course," said Ketter. "Further studies are needed to explore these preliminary observations."
Ketter, who received support for his work from the National Institute of Mental Health and the Holland Foundation, is continuing studies on the disorder and plans to investigate the use of brain imaging to predict patients' responses to medications and the use of psychotherapies as alternatives to mood stabilizers.
Ketter's co-investigators in this chart review include Cecylia Nowakowska, MD, PhD; Anna Sapozhnikova; Rebecca Chandler; Andrea Alarcon; Po Wang, MD; and Wendy Marsh, MD.
'"/>
Contact: Michelle Brandt
mbrandt@stanford.edu
650-723-0272
Stanford University Medical Center
5-May-2004
Page: 1 2 3 Related medicine news :1.
New Approach To Attacking Alzheimers Disease Studied2.
Treatment guidelines for kids with bipolar disorder published3.
Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder4.
Imaging tool may help physicians diagnose bipolar disorder5.
Capsules may be effective in treating bipolar disorder6.
UIC team develops new screening tool for pediatric bipolar disorder7.
New data shows Seroquel achieves remission in bipolar mania8.
Seroquel: New data show efficacy and tolerablity in bipolar depression9.
One-drug therapy approach to treating bipolar disorder10.
New drug-and-psychotherapy program for bipolar disorder in children11.
Astrazeneca receives European approval for Seroquel; in bipolar mania